MARLBOROUGH, Mass.,
Dec. 4, 2018 /PRNewswire/
-- Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a
biotechnology company developing the next generation of
immuno-oncology therapeutics based on its proprietary
self-delivering RNAi (sd-rxRNA®) therapeutic platform, announced
that Dr. Gerrit Dispersyn, President and Chief Operating Officer,
will give a presentation at the Tumor Targeted Lymphocytes Summit
being held at the Hilton Boston Back Bay in Boston on December
11-13.
Logo:
https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Dr. Dispersyn's presentation, titled "Therapeutic Enhancement of
TILs with Self-Delivering RNAi through Targeted Gene Silencing,"
will take place at 12:10 p.m. ET on
Thursday, December 13. He will present an overview on the
use of RNAi to improve the immunobiology of tumor infiltrating
lymphocytes (TILs) and other immune effector cells, how its use
compares to other approaches in Adoptive Cell Therapies (ACT), and
considerations for clinical and commercial applicability.
Dr. Dispersyn's presentation will be available under the
"Investors – Events and Presentations" section of the Company's
website, www.phiopharma.com, approximately one hour following the
presentation.
The Tumor Targeted Lymphocytes Summit is focused on the topic of
optimizing the clinical translation of TILs and endogenous T cells
to improve the efficacy of ACT.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a
biotechnology company developing the next generation of
immuno-oncology therapeutics based on its self-delivering RNAi
(sd-rxRNA®) therapeutic platform. The Company's discovery and
research efforts are focused on developing sd-rxRNA therapeutic
compounds to be used in the context of adoptive cell transfer by
targeting checkpoints or other gene targets, or to be used in
immunotherapy following intratumoral injection. We aim to maximize
the power of our sd-rxRNA therapeutic compounds by weaponizing
therapeutic immune effector cells to attack cancer, and to make
tumors more susceptible to such attacks, and ultimately provide
patients battling cancers with a powerful new treatment option that
goes beyond current treatment modalities. For additional
information, visit the Company's
website, www.phiopharma.com.
Contact
Phio Pharmaceuticals Corp.
ir@phiopharma.com
View original
content:http://www.prnewswire.com/news-releases/phio-pharmaceuticals-to-present-at-the-tumor-targeted-lymphocytes-summit-in-boston-on-december-13-300759371.html
SOURCE Phio Pharmaceuticals Corp.